Targeting auto-antibodies for CIDP: hope and questions

Despite the availability of evidence-based treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), their use frequently results in incomplete recovery.1 Intravenous immunoglobulins, plasma exchange, and corticosteroids might improve function in some, but not all, people with CIDP. No trials involving other agents have, to date, shown a benefit.2 Side-effect profiles, tolerability, logistics for intravenous infusions, and difficulties of long-term venous access are additional barriers to effective treatment for patients with CIDP.